BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31048689)

  • 1. MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF
    Sale MJ; Balmanno K; Saxena J; Ozono E; Wojdyla K; McIntyre RE; Gilley R; Woroniuk A; Howarth KD; Hughes G; Dry JR; Arends MJ; Caro P; Oxley D; Ashton S; Adams DJ; Saez-Rodriguez J; Smith PD; Cook SJ
    Nat Commun; 2019 May; 10(1):2030. PubMed ID: 31048689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma.
    Deuker MM; Marsh Durban V; Phillips WA; McMahon M
    Cancer Discov; 2015 Feb; 5(2):143-53. PubMed ID: 25472943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diverse alterations associated with resistance to KRAS(G12C) inhibition.
    Zhao Y; Murciano-Goroff YR; Xue JY; Ang A; Lucas J; Mai TT; Da Cruz Paula AF; Saiki AY; Mohn D; Achanta P; Sisk AE; Arora KS; Roy RS; Kim D; Li C; Lim LP; Li M; Bahr A; Loomis BR; de Stanchina E; Reis-Filho JS; Weigelt B; Berger M; Riely G; Arbour KC; Lipford JR; Li BT; Lito P
    Nature; 2021 Nov; 599(7886):679-683. PubMed ID: 34759319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential contribution for ERK1 and ERK2 kinases in BRAF
    Bosso G; Cintra Herpst AC; Laguía O; Adetchessi S; Serrano R; Blasco MA
    Cell Death Differ; 2024 Jun; 31(6):804-819. PubMed ID: 38698060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF
    Muraki N; Kawabe N; Ohashi A; Umeda K; Katsuda M; Tomatsu A; Yoshida M; Komeda K; Minna JD; Tanaka I; Morise M; Matsushima M; Matsui Y; Kawabe T; Sato M
    Exp Cell Res; 2024 Jun; 439(1):114057. PubMed ID: 38679315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.
    Bekaii-Saab T; Phelps MA; Li X; Saji M; Goff L; Kauh JS; O'Neil BH; Balsom S; Balint C; Liersemann R; Vasko VV; Bloomston M; Marsh W; Doyle LA; Ellison G; Grever M; Ringel MD; Villalona-Calero MA
    J Clin Oncol; 2011 Jun; 29(17):2357-63. PubMed ID: 21519026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis.
    Mizumoto Y; Kyo S; Mori N; Sakaguchi J; Ohno S; Maida Y; Hashimoto M; Takakura M; Inoue M
    Cancer Sci; 2007 May; 98(5):652-8. PubMed ID: 17388789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Live-cell target engagement of allosteric MEKi on MEK-RAF/KSR-14-3-3 complexes.
    Marsiglia WM; Chow A; Khan ZM; He L; Dar AC
    Nat Chem Biol; 2024 Mar; 20(3):373-381. PubMed ID: 37919548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SMK-17, a MEK1/2-specific inhibitor, selectively induces apoptosis in β-catenin-mutated tumors.
    Kiga M; Nakayama A; Shikata Y; Sasazawa Y; Murakami R; Nakanishi T; Tashiro E; Imoto M
    Sci Rep; 2015 Feb; 5():8155. PubMed ID: 25640451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant BRAF induces DNA strand breaks, activates DNA damage response pathway, and up-regulates glucose transporter-1 in nontransformed epithelial cells.
    Sheu JJ; Guan B; Tsai FJ; Hsiao EY; Chen CM; Seruca R; Wang TL; Shih IM
    Am J Pathol; 2012 Mar; 180(3):1179-1188. PubMed ID: 22227015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomics and Phosphoproteomics Profiling of Drug-Addicted BRAFi-Resistant Melanoma Cells.
    Li B; Kong X; Post H; Raaijmakers L; Peeper DS; Altelaar M
    J Proteome Res; 2021 Sep; 20(9):4381-4392. PubMed ID: 34343000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteostatic reactivation of the developmental transcription factor TBX3 drives BRAF/MAPK-mediated tumorigenesis.
    Zhang Z; Wu Y; Fu J; Yu X; Su Y; Jia S; Cheng H; Shen Y; He X; Ren K; Zheng X; Guan H; Rao F; Zhao L
    Nat Commun; 2024 May; 15(1):4108. PubMed ID: 38750011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ciliogenesis-associated Kinase 1 Promotes Breast Cancer Cell Proliferation and Chemoresistance via Phosphorylating ERK1.
    He Y; Zhang X; Pan W; Zhang J; Zhu W; Zhang J; Shi J
    Int J Biol Sci; 2024; 20(7):2403-2421. PubMed ID: 38725848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ssGSEA score-based Ras dependency indexes derived from gene expression data reveal potential Ras addiction mechanisms with possible clinical implications.
    Yi M; Nissley DV; McCormick F; Stephens RM
    Sci Rep; 2020 Jun; 10(1):10258. PubMed ID: 32581224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Escape from G1 arrest during acute MEK inhibition drives the acquisition of drug resistance.
    Channathodiyil P; May K; Segonds-Pichon A; Smith PD; Cook SJ; Houseley J
    NAR Cancer; 2022 Dec; 4(4):zcac032. PubMed ID: 36267209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors.
    Sale MJ; Minihane E; Monks NR; Gilley R; Richards FM; Schifferli KP; Andersen CL; Davies EJ; Vicente MA; Ozono E; Markovets A; Dry JR; Drew L; Flemington V; Proia T; Jodrell DI; Smith PD; Cook SJ
    Nat Commun; 2019 Nov; 10(1):5167. PubMed ID: 31727888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.
    Recondo G; Mezquita L; Facchinetti F; Planchard D; Gazzah A; Bigot L; Rizvi AZ; Frias RL; Thiery JP; Scoazec JY; Sourisseau T; Howarth K; Deas O; Samofalova D; Galissant J; Tesson P; Braye F; Naltet C; Lavaud P; Mahjoubi L; Abou Lovergne A; Vassal G; Bahleda R; Hollebecque A; Nicotra C; Ngo-Camus M; Michiels S; Lacroix L; Richon C; Auger N; De Baere T; Tselikas L; Solary E; Angevin E; Eggermont AM; Andre F; Massard C; Olaussen KA; Soria JC; Besse B; Friboulet L
    Clin Cancer Res; 2020 Jan; 26(1):242-255. PubMed ID: 31585938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reporter cell lines to screen for inhibitors or regulators of the KRAS-RAF-MEK1/2-ERK1/2 pathway.
    Weatherdon L; Stuart K; Cassidy M; de la Gándara AM; Okkenhaug H; Muellener M; Mckenzie G; Cook SJ; Gilley R
    Biochem J; 2024 Mar; 481(6):405-422. PubMed ID: 38381045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF - a tumour-agnostic drug target with lineage-specific dependencies.
    Hanrahan AJ; Chen Z; Rosen N; Solit DB
    Nat Rev Clin Oncol; 2024 Mar; 21(3):224-247. PubMed ID: 38278874
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.